DOCSLIB.ORG

IP Pragmatics Microbiome White Paper June 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IP Pragmatics Microbiome White Paper June 2017 JUNE 2017 EXPLOITING THE MICROBIOME: MARKET DEVELOPMENTS AND INTELLECTUAL PROPERTY LANDSCAPE Primary Authors: Scott McKellar, Kyriakos Tzafestas & Sophie Brayne Sector Lead: Ronnie Georghiou IP Pragmatics Limited London | Edinburgh | Sydney www.ip-pragmatics.com 2 | P a g e CONTENTS Contents ..................................................................................................................................... 2 Executive Summary .................................................................................................................... 4 Introduction ................................................................................................................................ 5 Market Overview ...................................................................................................................... 10 Human Health and Wellbeing .............................................................................................. 10 Therapeutics ..................................................................................................................... 13 Food & Nutrition ............................................................................................................... 17 Diagnostics ........................................................................................................................ 18 Animal Health ....................................................................................................................... 23 Sustainable Farming ......................................................................................................... 24 Animal Health and Welfare .............................................................................................. 25 Enzyme Discovery ............................................................................................................. 26 Livestock Productivity ....................................................................................................... 27 Plants and Agriculture .......................................................................................................... 28 Food Production & Food Security .................................................................................... 28 Deals ......................................................................................................................................... 31 Human Health and Wellbeing .............................................................................................. 31 Animal Health ....................................................................................................................... 33 Plants and Agriculture .......................................................................................................... 34 Pipeline ..................................................................................................................................... 36 Key Players................................................................................................................................ 37 Human Health and Wellbeing .............................................................................................. 39 4D Pharma ........................................................................................................................ 41 Enterome Bioscience ........................................................................................................ 42 Evelo Biosciences .............................................................................................................. 43 Second Genome ............................................................................................................... 44 Seres Therapeutics ........................................................................................................... 45 Synlogic ............................................................................................................................. 46 Vedanta Biosciences ......................................................................................................... 47 Research Landscape ......................................................................................................... 48 Animal Health ....................................................................................................................... 50 Research Landscape ......................................................................................................... 50 Plants and Agriculture .......................................................................................................... 51 © IP Pragmatics Ltd, 2017 www.ip-pragmatics.com 3 | P a g e Indigo Agriculture ............................................................................................................. 51 AgBiome ........................................................................................................................... 52 BioAg Alliance ................................................................................................................... 52 Research Landscape ......................................................................................................... 53 Market Drivers and Trends ....................................................................................................... 55 Human Health and Wellbeing .............................................................................................. 55 Animal Health ....................................................................................................................... 56 Plants and Agriculture .......................................................................................................... 56 Barriers to Entry ....................................................................................................................... 57 Patent Analysis ......................................................................................................................... 62 Patent Publishing Trends ...................................................................................................... 62 Key Entities ........................................................................................................................... 63 Cluster by Entity Type: Commercial vs. Academic ........................................................... 64 Geographical Analysis ........................................................................................................... 65 Technology areas .................................................................................................................. 67 Patent Landscaping .............................................................................................................. 69 Key Patents ........................................................................................................................... 74 Forward Citation Analysis ................................................................................................. 74 Backward Citation Analysis ............................................................................................... 77 Commentary on Granting of Patents ................................................................................... 79 Appendix ................................................................................................................................... 82 Appendix 1: Deals ............................................................................................................. 82 Appendix 2: Pipeline ....................................................................................................... 101 © IP Pragmatics Ltd, 2017 www.ip-pragmatics.com 4 | P a g e EXECUTIVE SUMMARY The intention of this white paper is to provide an overview of the market developments across the microbiome commercial and patent landscapes. The information in this report does not constitute legal advice and should not be interpreted as such. The academic, market and patent trends show that the microbiome industry is at an early stage but has been undergoing rapid growth over the last two years. In particular, therapeutics based on the human gut microbiome are a source of enormous commercial potential, as indicated by several licensing deals completed in 2016 which are worth hundreds of millions of dollars each. There are no marketed microbiome based drugs currently on the market, but the first drugs and diagnostics could launch by 2018. For the purposes of this report, the market has been segmented into three areas: human health and wellbeing, animal health and plants and agriculture. Most activity is still in the academic space. Academic microbiome research is highly active across all three market segments, and this is supported by a large amount of governmental funding and national and international research programs in several developed countries. Human health is by far the largest industry sector. In this area, and in plants and agriculture, a handful of multinational healthcare companies are increasingly partnering with a range of smaller biotech companies, start-ups and/or best-in-class academic institutions to develop or license microbiome products. The key areas of interest are in drugs to tackle diseases like gastrointestinal disorders, cancer and diabetes. Venture capital (VC) firms in the U.S. and Europe have recently become active in microbiome technologies. VC firms have invested around $1 billion
Load more

Recommended publications
  • The Bio Revolution: Innovations Transforming and Our Societies, Economies, Lives
    The Bio Revolution: Innovations transforming economies, societies, and our lives economies, societies, our and transforming Innovations Revolution: Bio The The Bio Revolution Innovations transforming economies, societies, and our lives May 2020 McKinsey Global Institute Since its founding in 1990, the McKinsey Global Institute (MGI) has sought to develop a deeper understanding of the evolving global economy. As the business and economics research arm of McKinsey & Company, MGI aims to help leaders in the commercial, public, and social sectors understand trends and forces shaping the global economy. MGI research combines the disciplines of economics and management, employing the analytical tools of economics with the insights of business leaders. Our “micro-to-macro” methodology examines microeconomic industry trends to better understand the broad macroeconomic forces affecting business strategy and public policy. MGI’s in-depth reports have covered more than 20 countries and 30 industries. Current research focuses on six themes: productivity and growth, natural resources, labor markets, the evolution of global financial markets, the economic impact of technology and innovation, and urbanization. Recent reports have assessed the digital economy, the impact of AI and automation on employment, physical climate risk, income inequal ity, the productivity puzzle, the economic benefits of tackling gender inequality, a new era of global competition, Chinese innovation, and digital and financial globalization. MGI is led by three McKinsey & Company senior partners: co-chairs James Manyika and Sven Smit, and director Jonathan Woetzel. Michael Chui, Susan Lund, Anu Madgavkar, Jan Mischke, Sree Ramaswamy, Jaana Remes, Jeongmin Seong, and Tilman Tacke are MGI partners, and Mekala Krishnan is an MGI senior fellow.
    [Show full text]
  • UBIOME, INC., Debtor. Chapter 11 Case No. 19
    Case 19-11938-LSS Doc 2 Filed 09/04/19 Page 1 of 42 IN IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: Chapter 11 UBIOME, INC.,1 Case No. 19-_____ (___) Debtor. DECLARATION OF CURTIS G. SOLSVIG III IN SUPPORT OF THE DEBTOR’S CHAPTER 11 PETITION AND REQUESTS FOR FIRST DAY RELIEF I, Curtis G. Solsvig III, hereby declare under penalty of perjury, pursuant to section 1746 of title 28 of the United States Code, as follows: 1. I am the Acting Chief Executive Officer (the “Acting CEO”) of uBiome, Inc., the debtor and debtor in possession in the above-captioned chapter 11 case (the “Debtor” or “uBiome”). 2. On or about May 24, 2019, I was originally retained by uBiome to provide financial consulting services, and on June 27, 2019,2 I was appointed by a special committee of the board to serve as the Debtor’s Acting CEO. As a Managing Director for Goldin Associates, LLC (“Goldin”), I have more than 30 years of experience in the turnaround industry, both as a restructuring advisor and as an interim manager, including chief executive officer or chief restructuring officer. My experience includes fiduciary and non-fiduciary roles in the restructurings or liquidations of, among others, Lily Robotics, Inc., Real Industries, Quiksilver, Borders Books, Restoration Hardware, Manischewitz Foods, Atari, Cornerstone Propane and Ports America. I have extensive expertise in the fund management business, including portfolio 1 The Debtor and the last four digits of its taxpayer identification number is: uBiome, Inc. (0019). The Debtor’s headquarters is located at 360 Langton Street, Suite 301, San Francisco, CA 94103.
    [Show full text]
  • Philosophy and Practice of Bioethics Across and Between Cultures
    Philosophy and Practice of Bioethics across and between Cultures Editors: Takao Takahashi, Nader Ghotbi & Darryl R. J. Macer Eubios Ethics Institute 2019 ii Philosophy and Practice of Bioethics Across and Between Cultures Eubios Ethics Institute Christchurch Tsukuba Science City Bangkok Cataloging-in-Publication data Philosophy and Practice of Bioethics across and between Cultures / Takahashi, Takao / Ghotbi, Nader / Macer, Darryl R.J. Christchurch, N.Z.: Eubios Ethics Institute ©2019. Copyright © 2019 Eubios Ethics Institute All rights reserved. The copyright for the complete publication is held by the Eubios Ethics Institute. The material may be used in education provided the copies are provided free of charge. No part of this publication may be reproduced for commercial use, without the prior written permission of the Eubios Ethics Institute. http://www.eubios.info/ 1 v. 22 Chapters. ISBN 978-0-908897-33-9 1. Bioethics. 2. Medical ethics. 3. Ethics. 4. Peace. 5. Philosophy. 6. Justice. 7. Disaster. 8. Information technology ethics. 9. Japan. 10. Asian Studies. 2. I. Takahashi, Takao, 1948. II. Ghotbi, Nader, 1967. III. Macer, Darryl Raymund Johnson, 1962. IV. Eubios Ethics Institute. V. Title (Philosophy and Practice of Bioethics across and between Cultures). The Eubios Ethics Institute is a nonprofit group that aims to stimulate the discussion of ethical issues, and how we may use new technology in ways consistent with "good life". An important part of this dialogue is to function as an information source for those with similar concerns. Publications are available through the website www.eubios.info, and refer to the ordering guidelines in this book. The views expressed in this book do not necessarily represent the views of the Eubios Ethics Institute, nor the editors.
    [Show full text]
  • Understanding Users Information Needs and Collaborative Sensemaking of Human Microbiome Data
    Understanding Users Information Needs and Collaborative Sensemaking of Human Microbiome Data ANONYMOUS AUTHOR(S)∗ Recent years are seeing a sharp increase in the availability of personal ’omic’ (e.g. genomes, microbiomes) data to non-experts through direct-to-consumer testing kits. While the scientific understanding of human -omic information is evolving, the interpretation of the data may impact well-being of users and relevant others, and therefore poses challenges and opportunities for CSCW research. We identify the information, interaction, and sense-making needs of omic data users, within the broader context of social omics - the sharing and collaborative engagement with data and interpretation. Analyzing users’ discussions on Reddit’s r/HumanMicrobiome, we identified seven user needs: reviewing an annotated report, comparing microbiome data, tracking changes, receiving personalized actionable information, curating information, controlling information, and documenting and sharing self experiments. We highlight the ways in which users interact with each other to collaboratively make sense of the data. We conclude with design implications, including tools for better communication with care providers, and for symptom-centered sharing and discussion. CCS Concepts: • Human-centered computing → Empirical studies in collaborative and social com- puting. Additional Key Words and Phrases: online communities, microbiome, collaborative sensemaking ACM Reference Format: Anonymous Author(s). 2019. Understanding Users Information Needs and Collaborative Sensemaking of Human Microbiome Data. 1, 1 (April 2019), 22 pages. https://doi.org/10.1145/nnnnnnn.nnnnnnn 1 INTRODUCTION In recent years, there has been a sharp increase in the availability of personal ’omic’ data (e.g. genomes, microbiomes) to non-experts through direct-to-consumer testing kits.
    [Show full text]
  • Temporary Policy Emergency Provisions For
    MEDICAL POLICY Temporary Policy Emergency Provisions for: Direct-to-Consumer and Over-the- Counter Testing Effective Date: 6/1/2021 Medical Policy Number: 73 Medical Policy Committee Approved Date: 8/18; 8/19; 2/2020; 7/2020; 9/2020; 2/2021 6/1/2021 Medical Officer Date See Policy CPT/HCPCS CODE section below for any prior authorization requirements NEED AND DURATION OF EMERGENCY PROVISIONS 1. Need for the temporary Provisions: COVID-19 public health emergency 2. Documents or source relied upon: Families First Coronavirus Response Act (FFCRA) and the Coronavirus Aid, Relief, and Economic Security (CARES) Act1-4 3. Initial Effective Date: 8/1/2020 4. Re-review dates: 9/23/2020; 11/30/2020; 2/1/2021; 3/31/2021; 6/1/2021 5. Termination Date: 12/31/2021 6. Next Reassessment Date determined at Companies sole discretion: 12/30/2021 POLICY ADDENDUM Applies To: Commercial, ASO, and Medicare Effective for Dates of Service: 2/26/2021 onward COVID-19 Public Health Emergency Under section 6001 of the Families First Coronavirus Response Act (FFCRA) and section 4201 of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, health plans must provide coverage of in vitro diagnostic products for the detection or diagnosis of SARS-CoV-2 or COVID-19 that are approved by the U.S. Food and Drug Administration (FDA).1,2 On June 23, 2020, the Department of Labor (DOL), Department of Health and Human Services (DHHS), and the Department of the Treasury (collectively, the Departments) jointly released an FAQ around the FFCRA and CARES act implementation.3 This FAQ (see question 4) indicates that COVID-19 tests intended for at-home testing must be covered.
    [Show full text]
  • Determination of Strategic Priorities for a Microbiome Company Through Analysis of Technical Capabilities and Current Market Landscapes
    DETERMINATION OF STRATEGIC PRIORITIES FOR A MICROBIOME COMPANY THROUGH ANALYSIS OF TECHNICAL CAPABILITIES AND CURRENT MARKET LANDSCAPES by BRANDON EDWARD ANDREW Submitted in fulfillment of the requirements for the degree of Master of Science Thesis Advisors: Dr. Christopher Cullis, Dr. Emmitt Jolly, Dr. Neema Mayhugh Department of Biology CASE WESTERN RESERVE UNIVERSITY May 2020 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Brandon Edward Andrew candidate for the degree of Master of Science. Committee Member Christopher Cullis Committee Member Emmitt Jolly Committee Member Neema Mayhugh Date of Defense April 2, 2020 *We also certify that written approval has been obtained for any proprietary material contained therein. 2 Table of Contents I. Technical and Scientific Background I.I Human Microbiome and Large-Scale Research Initiatives…………………..…….1 I.II Some notes on the design of current studies in microbiome-related research……………………………………………………………………….………..6 I.III Metagenomics and Sequencing Methods for Microbiome Characterization……………………………………………………………...….……..7 I.IV 16S and 18S rRNA Sequencing ………………………..………………………...9 I.V Whole Genome Sequencing: Coverage, Read Length, and Depth……………….12 I.VI Gut Microbiome and the Fungal Connection: Dr. Ghannoum’s Research ……...15 I.VII Crohn’s Disease, Ulcerative Colitis, and Irritable Bowel Disease ……………..20 II. Business Development Strategy and Commercialization Roadmap II.I Biohm’s Current Business Model ……………………………..……………………22 II.II Medical
    [Show full text]
  • Understanding Users Information Needs and Collaborative Sensemaking of Microbiome Data
    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/335474448 Understanding Users Information Needs and Collaborative Sensemaking of Microbiome Data Article in Computer Supported Cooperative Work · August 2019 DOI: 10.1145/3274470 CITATIONS READS 0 201 5 authors, including: Orit Shaer Oded Nov Wellesley College New York University 99 PUBLICATIONS 2,105 CITATIONS 118 PUBLICATIONS 3,573 CITATIONS SEE PROFILE SEE PROFILE Some of the authors of this publication are also working on these related projects: HoloMuse View project HCI for Personal Genomics View project All content following this page was uploaded by Orit Shaer on 29 August 2019. The user has requested enhancement of the downloaded file. Understanding Users Information Needs and Collaborative Sensemaking of Microbiome Data JENNIFER OTIONO∗, Wellesley College MONSURAT OLAOSEBIKAN∗, Tufts University ORIT SHAER, Wellesley College ODED NOV, New York University MAD PRICE BALL, Open Humans Foundation Recent years are seeing a sharp increase in the availability of personal omic (e.g. genomes, microbiomes) data to non-experts through direct-to-consumer testing kits. While the scientifc understanding of human -omic information is evolving, the interpretation of the data may impact well-being of users and relevant others, and therefore poses challenges and opportunities for CSCW research. We identify the information, interaction, and sense-making needs of microbiomic data users, within the broader context of social omics - the sharing and collaborative engagement with data and interpretation. Analyzing users’ discussions on Reddit’s r/HumanMicrobiome, we identifed seven user needs for microbiome data: reviewing an annotated report, comparing microbiome data, tracking changes, receiving personalized actionable information, curating and securing information, documenting and sharing self experiments, and enhancing the communication between patients and health-care providers.
    [Show full text]
  • Development and Validation of a Taxonomy for Characterizing Measurements in Health Self-Quantification
    JOURNAL OF MEDICAL INTERNET RESEARCH Almalki et al Original Paper Development and Validation of a Taxonomy for Characterizing Measurements in Health Self-Quantification Manal Almalki1,2*, PhD; Kathleen Gray1*, PhD; Fernando Martin-Sanchez1,3*, PhD 1Health and Biomedical Informatics Centre, Melbourne Medical School, The University of Melbourne, Melbourne, Australia 2Faculty of Public Health and Tropical Medicine, Health Informatics Dept., Jazan University, Jazan, Saudi Arabia 3E-Health Research Unit, National Institute of Health Carlos III, Madrid, Spain *all authors contributed equally Corresponding Author: Manal Almalki, PhD Faculty of Public Health and Tropical Medicine Health Informatics Department Jazan University Level 1 Prince Ahmed Bin Abdulaziz Street Jazan, 82726 Saudi Arabia Phone: 966 173210584 ext 102 Fax: 966 173210579 Email: [email protected] Abstract Background: The use of wearable tools for health self-quantification (SQ) introduces new ways of thinking about one's body and about how to achieve desired health outcomes. Measurements from individuals, such as heart rate, respiratory volume, skin temperature, sleep, mood, blood pressure, food consumed, and quality of surrounding air can be acquired, quantified, and aggregated in a holistic way that has never been possible before. However, health SQ still lacks a formal common language or taxonomy for describing these kinds of measurements. Establishing such taxonomy is important because it would enable systematic investigations that are needed to advance in the use of wearable tools in health self-care. For a start, a taxonomy would help to improve the accuracy of database searching when doing systematic reviews and meta-analyses in this field. Overall, more systematic research would contribute to build evidence of sufficient quality to determine whether and how health SQ is a worthwhile health care paradigm.
    [Show full text]
  • Initial Sequencing and Characterization of Gastrointestinal
    bioRxiv preprint doi: https://doi.org/10.1101/419598; this version posted September 18, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Initial Sequencing and Characterization of Gastrointestinal and Oral Microbiota in Urban Pakistani Adults Reveals Abnormally High Levels of Potentially Starch Metabolizing Bacteria in the General Population Maria Batool1, Syed Baqir Ali1, Ali Jaan1, Kehkishan Khalid1, Syeda Aba Ali1, Kainat Kamal1, Afraz Ahmed Raja1, Farzana Gul1, Inti Pedroso2, Zachary Apte2, and Arshan Nasir1,* 1Department of Biosciences, COMSATS University Islamabad, Park Road, Tarlai Kalan, Islamabad 45550, Pakistan 2uBiome, San Francisco, CA, United States *Correspondence: Arshan Nasir ([email protected], [email protected]) ABSTRACT We describe the characterization of the gastrointestinal tract (gut) and oral microbiota (bacteria) in 32 urban Pakistani adults representing seven major geographies and six ethnicities in the country. Study participants were between ages 18 and 40, had body mass index between 18 and 25 Kg/m2, and were early-career students or professionals belonging to 25 major cities of the country. These individuals donated a total of 61 samples (32 gut and 29 oral) that were subjected to 16S ribosomal RNA (rRNA) gene sequencing. Microbiome composition of Pakistani individuals was compared against the uBiome database of selected individuals who self-reported to be in excellent health. Using the crude measure of percentage overlap or similarity between the gut microbiota profile of Pakistani and uBiome dataset as proxy for health, our sequencing indicated that the Pakistani gut microbiota was moderately healthy relative to the uBiome dataset and Pakistani women appeared healthier relative to men.
    [Show full text]
  • Analyzing the Privacy and Societal Challenges Stemming from the Rise of Personal Genomic Testing
    UNIVERSITY COLLEGE LONDON DOCTORAL THESIS Analyzing the Privacy and Societal Challenges Stemming from the Rise of Personal Genomic Testing Author: Supervisor: Alexandros Mittos Prof. Emiliano De Cristofaro A thesis submitted in fulfillment of the requirements for the degree of Doctor of Philosophy in the Information Security Group Department of Computer Science December 15, 2020 iii Declaration of Authorship I, Alexandros Mittos, declare that this thesis titled, “Analyzing the Privacy and Soci- etal Challenges Stemming from the Rise of Personal Genomic Testing” and the work presented in it are my own. I confirm that: • This work was done wholly or mainly while in candidature for a research degree at this University. • Where any part of this thesis has previously been submitted for a degree or any other qualification at this University or any other institution, this has been clearly stated. • Where I have consulted the published work of others, this is always clearly at- tributed. • Where I have quoted from the work of others, the source is always given. With the exception of such quotations, this thesis is entirely my own work. • I have acknowledged all main sources of help. • Where the thesis is based on work done by myself jointly with others, I have made clear exactly what was done by others and what I have contributed myself. Signed: Date: v “Somewhere, something incredible is waiting to be known.” Carl Sagan vii Abstract Progress in genomics is enabling researchers to better understand the role of the genome in our health and well-being, stimulating hope for more effective and cost efficient healthcare.
    [Show full text]
  • Privacy-Preserving Microbiome Analysis Using Secure Computation
    bioRxiv preprint doi: https://doi.org/10.1101/025999; this version posted September 3, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Privacy-Preserving Microbiome Analysis Using Secure Computation Justin Wagner University of Maryland, College Park, Center for Bioinformatics and Computational Biology [email protected] Joseph N. Paulson University of Maryland, College Park, Center for Bioinformatics and Computational Biology ∗ Xiao-Shaun Wang University of Maryland, College Park, Maryland Cybersecurity Center Bobby Bhattacharjee University of Maryland, College Park, Maryland Cybersecurity Center H´ectorCorrada Bravo University of Maryland, College Park, Center for Bioinformatics and Computational Biologyy [email protected] Abstract 1 Introduction Motivation: Developing targeted therapeutics and iden- A significant application of DNA sequencing is studying tifying biomarkers relies on large amounts of patient the microbial communities that inhabit the human body. data. Beyond human DNA, researchers now investi- It is estimated that only 1 in 10 cells that reside in and gate the DNA of micro-organisms inhabiting the human on a person contain that individual's DNA [22]. Micro- body. An individual's collection of microbial DNA con- biome sequencing seeks to characterize and classify all of sistently identifies that person and could be used to link these non-human cells. Most of these microbes cannot be a real-world identity to a sensitive attribute in a research cultured and studied in the laboratory, therefore direct dataset.
    [Show full text]
  • PROTOCOL Biomedical
    PROTOCOL Protocol # 2016-04-8727 Biomedical Non- Date Printed: 10/04/2017 Exempt Berkeley Personnel Information 1 Vulnerable Subject Checklist 4 Study Sites 5 General Checklist 6 Funding 7 Expedited Paragraphs 10 Purpose, Background, Collaborative Research 13 Subject Population 16 Study Procedures, Alternatives to Participation 19 Radiation 22 Medical Equipment, Investigational Devices 23 Drugs, Reagents, or Chemicals 24 Risks and Discomforts 25 Benefits, Confidentiality 27 Potential Financial Conflict of Interest 30 Informed Consent 31 Child Assent & Parent Permission 33 HIPAA 35 Attachments 37 Assurance 40 PROTOCOL Protocol # 2016-04-8727 Biomedical Non- Date Printed: 10/04/2017 Exempt Berkeley Event History 42 PROTOCOL Protocol # 2016-04-8727 Biomedical Non- Date Printed: 10/04/2017 Exempt Berkeley Protocol Title: Impact of Soylent Consumption on Human Microbiome Composition Protocol Type: Biomedical Non-Exempt Date Submitted: 06/27/2016 Approval Period: Draft Important Note: This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol. Questions that appear to not have been answered may not have been required for this submission. Please see the system application for more details. ----------------------------------------------------------------------------------------------------1 * * * Personnel Information * * * Enter all UC Berkeley study personnel (if not previously entered) and relevant training information. Please read Personnel Titles and Responsibilities:
    [Show full text]